Clinical Trials Logo

Clinical Trial Summary

This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study. Primary objective: The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and rituximab plus CHOP, as first-line treatment of diffuse large B-cell lymphoma. Secondary objective: The purpose is to compare the safety of H02 combined with CHOP regimen and rituximab injection (Rituximab®) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05040906
Study type Interventional
Source Shandong New Time Pharmaceutical Co., LTD
Contact jianfeng zhou, Doctor
Phone 13627284963
Email [email protected]
Status Recruiting
Phase Phase 3
Start date October 13, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT01894971 - The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube Phase 3